Leerink Partnrs Weighs in on Cartesian Therapeutics, Inc.’s FY2027 Earnings (NASDAQ:RNAC)

Cartesian Therapeutics, Inc. (NASDAQ:RNAC) – Analysts at Leerink Partnrs issued their FY2027 earnings estimates for Cartesian Therapeutics in a report released on Tuesday, April 23rd. Leerink Partnrs analyst T. Smith expects that the company will earn ($7.10) per share for the year. Leerink Partnrs currently has a “Outperform” rating on the stock. The consensus estimate for Cartesian Therapeutics’ current full-year earnings is ($1.50) per share.

A number of other equities analysts also recently commented on the company. Needham & Company LLC began coverage on Cartesian Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $42.00 price objective on the stock. SVB Leerink began coverage on Cartesian Therapeutics in a report on Tuesday. They issued an “outperform” rating and a $39.00 price objective on the stock. Finally, HC Wainwright increased their price objective on Cartesian Therapeutics from $2.00 to $54.00 and gave the stock a “buy” rating in a report on Tuesday.

Cartesian Therapeutics Stock Performance

NASDAQ:RNAC opened at $20.90 on Wednesday. The stock has a 50 day moving average price of $19.26. Cartesian Therapeutics has a 52 week low of $11.66 and a 52 week high of $42.60.

Cartesian Therapeutics (NASDAQ:RNAC) last posted its quarterly earnings results on Thursday, March 7th. The company reported ($2.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.30) by ($2.10). Cartesian Therapeutics had a negative return on equity of 58.21% and a negative net margin of 845.01%. The company had revenue of $8.27 million during the quarter.

Hedge Funds Weigh In On Cartesian Therapeutics

An institutional investor recently bought a new position in Cartesian Therapeutics stock. Hall Laurie J Trustee acquired a new position in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 52,775 shares of the company’s stock, valued at approximately $34,000. Hall Laurie J Trustee owned about 0.98% of Cartesian Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 86.95% of the company’s stock.

Insider Buying and Selling at Cartesian Therapeutics

In related news, Director Timothy A. Springer purchased 21,612 shares of the stock in a transaction on Thursday, March 14th. The shares were bought at an average price of $16.20 per share, for a total transaction of $350,114.40. Following the completion of the acquisition, the director now directly owns 1,017,228 shares in the company, valued at approximately $16,479,093.60. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders have purchased a total of 22,472 shares of company stock worth $365,981 over the last 90 days. Insiders own 31.20% of the company’s stock.

Cartesian Therapeutics Company Profile

Cartesian Therapeutics, Inc, a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases.